搜索临床试验以:HspE7 和 Poly-ICLC
总计1295个结果
-
Samsung Medical Center完全的
-
Jiangsu Simcere Pharmaceutical Co., Ltd.G1 Therapeutics, Inc.完全的
-
Korea University Anam HospitalTakeda; Korean Cancer Study Group尚未招聘
-
Assistance Publique - Hôpitaux de Paris尚未招聘Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
-
National University Hospital, Singapore招聘中
-
Institute of Cancer Research, United KingdomAstraZeneca; Cancer Research UK招聘中
-
Mario Negri Institute for Pharmacological ResearchNorth Eastern German Society of Gynaecological Oncology主动,不招人
-
Matthew GalskyIcahn School of Medicine at Mount Sinai; AstraZeneca完全的
-
AstraZeneca完全的
-
UNICANCERClovis Oncology, Inc.; Fondation ARC完全的
-
Dana-Farber Cancer Institute撤销
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.尚未招聘BRCA1突变 | BRCA2突变 | PALB2基因突变 | 激素受体阳性 HER-2 阴性乳腺癌 | 晚期或转移性乳腺癌德国
-
Sun Yat-sen University招聘中
-
National Cancer Institute, Naples招聘中
-
Peter MacCallum Cancer Centre, Australia招聘中
-
National Cancer Institute (NCI)招聘中
-
Tango Therapeutics, Inc.终止乳腺癌 | 卵巢癌 | 前列腺癌 | 胰腺癌 | BRCA1突变 | BRCA-突变的卵巢癌 | BRCA 相关性乳腺癌 | HRD 阳性晚期卵巢癌美国
-
BayerGlaxoSmithKline终止
-
Institut BergoniéNational Cancer Institute, France完全的
-
Sunnybrook Health Sciences CentreGlaxoSmithKline招聘中
-
Zhejiang Cancer HospitalSun Yat-sen University; Fujian Cancer Hospital; Hunan Cancer Hospital; Zhejiang University; Taizhou...尚未招聘三阴性乳腺癌 | 同源重组缺陷
-
SOLTI Breast Cancer Research Group招聘中
-
Tongji HospitalSun Yat-sen University; Qilu Hospital of Shandong University; Hubei Cancer Hospital; Hunan Cancer... 和其他合作者招聘中
-
Laval UniversityCanadian Institutes of Health Research (CIHR); AstraZeneca招聘中
-
Spanish Breast Cancer Research GroupAstraZeneca完全的
-
Dana-Farber Cancer InstituteAstraZeneca撤销
-
Abramson Cancer Center at Penn Medicine终止
-
Memorial Sloan Kettering Cancer CenterClovis Oncology, Inc.主动,不招人